Micotil^® (tilmicosin injection)

Micotil is now approved for a flexible dose range from 10 mg/kg (1.5 mL/cwt) to 20 mg/kg (3.0 mL/cwt) for both metaphylaxis and individual pull-and-treat Bovine Respiratory Disease (BRD) therapy. The updated label also includes a new withdrawal time of 42 days, regardless of dose, and a maximum injection volume of 10 mL per injection site. Treatment claims for Pasteurella multocida and Histophilus somni were added in addition to Mannheimia haemolytica. Micotil is still indicated for the control of BRD associated with M. haemolytica. Ovine Respiratory Disease (ORD) indications have not changed

Micotil is the proven, fast-acting, long lasting BRD treatment that offers a flexible, cost-effective dose range for both metaphylaxis and individual pull and treat therapy.

In the lungs in one hour*

• Micotil reaches cattle’s lungs in one hour.¹
• Micotil reaches consolidated lungs in two hours.¹

Throughout the respiratory tract for three to four days

• Micotil maintains three to four days of effective concentration levels throughout the respiratory tract, including the pneumonic lung tissue¹, tracheal mucosa² and tonsils² — where the respiratory infectious process begins.

In the immune cells for at least 10 days

• Micotil maintains levels in alveolar macrophages³ and neutrophils⁴ for at least 10 days.

Micotil metaphylaxis controls BRD, reducing BRD pulls throughout the entire feeding period^5,6

*The clinical relevance of this in vitro data has not been demonstrated.

Important safety information

• Micotil is to be used by, or on the order of, a licensed veterinarian. For cattle or sheep, inject subcutaneously. Intravenous use in cattle or sheep will be fatal. Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cattle or sheep may cause milk residues.
• The following adverse reactions have been reported: in cattle: injection site swelling and inflammation, lameness, collapse, anaphylaxis/anaphylactoid reactions, decreased food and water consumption, and death; in sheep: dyspnea and death.
• Always use proper drug handling procedures to avoid accidental self-injection. Do not use in automatically powered syringes.
• Consult your veterinarian on the safe handling and use of all injectable products prior to administration.
• Micotil has a pre-slaughter withdrawal time of 42 days. See label on next page for complete use information, including boxed human warnings and non-target species safety information.

Product Information:

MSDS Info	Label
Safe Handling and Use Information
Client Info Sheet (English and Español)

 

To download PDF's, you'll need Adobe Acrobat Reader. If you don't have Adobe, you can download it for free.

Micotil^® is a registered trademark for Elanco's brand of tilmicosin injection.

¹Apley, M. 1997. Antimicrobial Therapy of Bovine Respiratory Disease. Veterinary Clinics of North America. Food Animal Practice. 13:559-562.

²Fossler, SC, JW Moran & TD Thomson. 1998. Pharmacologic Mechanism for Tilmicosin in the Control of Cattle Pneumonia. Proceedings of the 79th Annual Meeting of the Conference of Research Workers in Animal Diseases. p. 82.

³Fossler, SC. 2001. The Cellular Immune Response to Mannheimia Haemolytica-induced Bovine Respiratory Disease and the Ability of Tilmicosin to Concentrate within the Alveolar Macrophages and Peripheral Neutrophils. Elanco Animal Health, Indianapolis, IN. Elanco Study T5C760004.

⁴Fossler, SC, JW Moran, MA Martinez & TD Thomson. 2000. Distribution of Tilmicosin into Bovine Peripheral Neutrophils Following Micotil Treatment. Proceedings of the 81st Annual Meeting of the Conference of Research Workers in Animal Diseases. p. 101.

⁵Mechor, GD. 2005. The Effects of Metaphylaxis with Micotil® on Health and Performance of Northern Calves at High Risk of Contracting Bovine Respiratory Disease. Elanco Animal Health, Indianapolis, IN. Elanco Study T5CB30206.

⁶Mechor, GD & GJ Vogel. 2004. The Effects of Metaphylaxis with Micotil® on Health and Performance of Calf-fed Holsteins at High Risk of Contracting Bovine Respiratory Disease. Elanco Animal Health, Indianapolis, IN. Elanco Study T5CB30107.